Fellowship · Sacramento, CA
Sponsored by University of California Davis Health · Director Rebecca Brooks
Uterine Neoplasms, Version 1.2023, NCCN Clinical Practice Guidelines in Oncology.
Journal of the National Comprehensive Cancer Network : JNCCN · 2023 · 486 citations · Rebecca Brooks
Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer.
The New England journal of medicine · 2023 · 633 citations · Eugenia Girda
NCCN Guidelines® Insights: Cervical Cancer, Version 1.2024.
Journal of the National Comprehensive Cancer Network : JNCCN · 2023 · 349 citations · Rebecca Brooks
NCCN Guidelines® Insights: Ovarian Cancer, Version 3.2022.
Journal of the National Comprehensive Cancer Network : JNCCN · 2022 · 346 citations · Gary Leiserowitz
NCCN Guidelines® Insights: Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer, Version 3.2024.
Journal of the National Comprehensive Cancer Network : JNCCN · 2024 · 127 citations · Gary Leiserowitz
Real-world application of tumor mutational burden-high (TMB-high) and microsatellite instability (MSI) confirms their utility as immunotherapy biomarkers.
ESMO open · 2022 · 289 citations · Eugenia Girda
Vulvar Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology.
Journal of the National Comprehensive Cancer Network : JNCCN · 2024 · 85 citations · Rebecca Brooks
NCCN Guidelines® Insights: Uterine Neoplasms, Version 3.2025.
Journal of the National Comprehensive Cancer Network : JNCCN · 2025 · 55 citations · Rebecca Brooks